The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.

@article{Lindsley2008ThePP,
  title={The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.},
  author={Craig W Lindsley and Stanley F Barnett and Mark E Layton and Mark T Bilodeau},
  journal={Current cancer drug targets},
  year={2008},
  volume={8 1},
  pages={7-18}
}
This article describes recent advances in the development and biological evaluation of allosteric and ATP-competitive small molecule inhibitors for the serine/threonine kinase Akt (protein kinase B, PKB). Unregulated activation of the PI3K/Akt/PTEN pathway is a prominent feature of many human cancers and Akt is over-expressed or activated in all major cancers making Akt an exciting new target for cancer therapy. The development of Akt inhibitors has been complicated and hampered by the presence… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

The podocyte under stress: AKT2 to the rescue.

American journal of kidney diseases : the official journal of the National Kidney Foundation • 2014
View 2 Excerpts

Therapeutic Targeting of Integrin αvβ6 in Breast Cancer

Journal of the National Cancer Institute • 2014
View 2 Excerpts

Similar Papers

Loading similar papers…